AUSTIN, Texas, July 18, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a leader in personalized genetic testing and diagnostics, today announced that the Federal Circuit Court of Appeals affirmed the Delaware Federal District Court's September 2021 decision that all three CareDx patents asserted against Natera are invalid for claiming patent-ineligible subject matter.
Read more at prnewswire.comFederal Circuit Rules in Favor of Natera, Upholding Invalidation of CareDx Patents
PR Newswire -
Mon Jul 18, 2022
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/NVIDIA%20Corp%20logo%20on%20phone-by%20Evolf%20via%20Shutterstock.jpg)
/Amazon%20-%20Image%20by%20bluestork%20via%20Shutterstock.jpg)
